COVID vaccine boosters called into question by FDA chief: ‘Void of data'
The FDA chief has called into question whether the agency will approve and authorize the COVID-19 vaccine for winter.
In August 2024, the U.S. Food and Drug Administration approved the updated mRNA COVID vaccine to protect against the current variants, and also approved an updated Novavax vaccine.
FDA Commissioner Dr. Marty Makary, however, has expressed doubts about whether that is necessary for the 2025-2026 season.
Dementia Risk Could Dip With Common Vaccine, Study Suggests
"We're taking a look. I can't comment on any particular application. As you know, we have a bunch of applications for those booster shots," Makary told CBS News on Tuesday, as the outlet reported.
"I think there's a void of data. And I think rather than allow that void to be filled with opinions, I'd like to see some good data," he added.
Read On The Fox News App
Makary also mentioned a "public trust problem" surrounding COVID boosters, noting that many healthcare workers opted out of receiving them last season.
Flu Vaccine Linked To Higher Infections, Says Early Research
The FDA chief has also expressed concerns about the lack of data supporting Novavax's COVID vaccine, calling for more studies into its effectiveness before approving it.
"The big Novavax 2020-2021 study excluded people with natural immunity to COVID. Today, there is broad population immunity, and the big question is, does it provide a benefit?" he said in an interview with Inside Medicine on Tuesday.
"Without a study on the new formulation and product, we can't give an honest, evidence-based answer to that question."
Novavax on Tuesday posted an update on its website of the FDA's request for an additional clinical trial.
"It's my general feeling, not with this particular product, which I can't discuss in-depth, but with drugs in general, that we need to know if they work today in order to be able to recommend them," Makary told CBS News on Tuesday.
Click Here To Sign Up For Our Health Newsletter
The Centers for Disease Control and Prevention (CDC) has also been considering narrowing the recommendations for widespread COVID vaccines starting in 2025-2026.
In an April report, the agency presented three options for COVID boosters: to maintain the "universal vaccine policy" for everyone aged 6 months and older, to only recommend them for groups at high risk of severe COVID illness, or to use risk-based recommendations up to 64 years of age and then switch to universal recommendations at age 65.
The main risk factors for severe disease include advancing age, underlying medical conditions and pregnancy, the CDC stated.
For more Health articles, visit www.foxnews.com/health
Those who work in healthcare or who live in long-term care facilities are at increased risk of exposure.Original article source: COVID vaccine boosters called into question by FDA chief: 'Void of data'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
36 minutes ago
- Scientific American
Inside the Collapse of the America's Overdose Prevention Program
At an addiction conference in Nashville, Tenn., in late April, U.S. Secretary of Health and Human Services Robert F. Kennedy, Jr., spoke about his own experience with drug use. 'Addiction is a source of misery. It's also a symptom of misery,' he said. Kennedy's very personal speech, however, ignored recent federal budget cuts and staffing reductions that could undo national drug programs' recent progress in reversing overdoses and treating substance use. Several experts in the crowd, including Caleb Banta-Green, a research professor at the University of Washington, who studies addiction, furiously spoke up during Kennedy's speech. Banta-Green interrupted, shouting 'Believe science!' before being removed from the venue. (The Department of Health and Human Services did not respond to a request for comment for this article.) 'I had to stand up and say something,' says Banta-Green, who has spent his career working with people who use drugs and was a senior science adviser at the Office of National Drug Control Policy during the Obama administration. 'The general public needs to understand what is being dismantled and the very real impact it's going to have on them and their loved ones.' On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. The Trump administration has defunded public health programs and made plans to consolidate or eliminate the systems that track their outcomes, making it difficult to monitor the deadly consequences of substance use, Banta-Green says. For instance, staff cuts to the Overdose Data to Action program and the Opioid Overdose Prevention and Surveillance program will hamper former tracking efforts at the Centers for Disease Control and Prevention and at local and state health departments' prevention programs. A recently fired policy analyst at the overdose prevention division at the CDC's National Center for Injury Prevention and Control— who wishes to remain anonymous, citing fear of retaliation—tells Scientific American that she used to provide policy support to teams at health departments in 49 states and shared public overdose data and information to Congress. She is a veteran who should have had protected employment status, but she lost her job during federal cuts in February. 'No one else is doing surveillance and data collection and prevention like the CDC was,' she says. 'There's so much that's been cut.' (When approached for an interview by Scientific American, a CDC spokesperson said, 'Honestly, the new administration has changed how things normally work' and did not make anyone available for questions.) What Gets Measured Gets Managed Provisional data suggest that deaths from drug use declined by almost 25 percent in 2024, though overdoses remain the leading cause of death for Americans aged 18 to 44. Cuts to the National Survey on Drug Use and Health will make it difficult to measure similar statistics in the future. Because substance use is highly stigmatized, Banta-Green says it's important to have diverse, localized and timely data from multiple agencies to accurately capture the need for services—and the ways they're actually used. 'You can't design public health or policy responses if you don't know the scale of the need,' he says. Overdose trends vary by region—for example, usage of the synthetic opioid fentanyl appeared earlier on the East Coast than the West—so national averages can obscure critical local patterns. These regional differences can offer important insights into which interventions might be working, Banta-Green says. For instance, important medications such as naloxone rapidly reverse opioid overdoses in emergency situations. But getting people onto long-term medications, including methadone and buprenorphine, which reduce cravings and withdrawal symptoms, can more effectively prevent mortality in both the short and long term. Declining deaths may also mask tragic underlying dynamics. Successful interventions may not be the only cause of a drop in overdoses; it could also be that the people who are most vulnerable to overdose have recently perished and that there are simply fewer remaining at risk. 'It's like a forest fire burning itself out,' Banta-Green says. This underscores the need for the large-scale data collection threatened by the proposed budget and staff cuts at the CDC and National Institutes of Health, says Regina LaBelle, an addiction policy expert at Georgetown University. 'What [the administration is] doing is shortsighted' and doesn't appear to be based 'on the effectiveness or the outcomes of the programs that [it's] cutting,' she says. For example, despite promising to expand naloxone access, the Trump administration's latest budget proposal cuts funding for a critical program that distributes the lifesaving medication to first aid responders. 'A Chance at Redemption' When LaBelle was acting director of the White House Office of National Drug Control Policy during the Biden administration, she led efforts to expand evidence-based programs that provided clean syringes and tested users' drugs for harmful substances. These strategies are often referred to as 'harm reduction,' which LaBelle describes as 'a way you can meet people where they are and give them the services they need to keep them from dying.' José Martínez, a substance use counselor based in Buffalo, N.Y., says harm-reduction practices helped save his life. When Martínez got his first job as a peer advocate for people using drugs, he was still in a chaotic part of his own addiction and had been sleeping on the street and the subway—and regularly getting into fights—for a decade. The day after he was hired to help provide counseling on hepatitis C, he got into a New York City shelter. As his bruises healed, he learned life skills he was never taught at home. 'For a lot of people, drug use is a coping tool,' he says. 'The drug is rarely the problem. Drug use is really a symptom.' Working with others who understood that many people need help minimizing risks gave Martínez a chance to make progress toward recovery in a way that he says abstinence-only treatment programs couldn't. 'I don't agree that somebody should be sober in order for them to do things different,' he says. Over the past six years working for the National Harm Reduction Coalition, Martínez started a national support network for other peer program workers and community members—people who share their experiences and are a trusted source of education and support for others using drugs. 'There's never no time limit,' he says. 'Everybody works on their own pace.' Though Martínez's program doesn't take federal funding, the Trump administration is cutting similar kinds of peer programs. Martínez says doing this peer work gives many users a sense of purpose and stability—and helps them avoid previous behaviors. The proposed 2026 federal budget will slash the CDC's opioid surveillance programs by $30 million. It also creates a new subdivision called the Administration for a Healthy America that will consolidate the agency's prevention work, along with existing programs at the Substance Abuse and Mental Health Services Agency (SAMHSA), which often coordinates grants for treatment programs. The programs formerly conducted through SAMHSA are also facing cuts of more than $1 billion. Advocates fear this will include a shift toward funding abstinence-only priorities, which, Martínez says, 'will definitely mean that we're going to have more overdoses.' (Some research suggests abstinence-based treatment actually puts people at a higher risk of fatal overdose than those who receive no treatment at all.) 'The general public needs to understand what is being dismantled and the very real impact it's going to have on them and their loved ones.' —Caleb Banta-Green, addiction research professor These cuts could disproportionately affect communities already facing higher overdose rates: Martínez, who is Puerto Rican, notes that U.S. Black, Latino and Indigenous communities have experienced drug overdose death increases in recent years. In many states, overdose deaths in Black and brown communities remain high while white overdose death rates are declining. Looming cuts to Medicaid programs, LaBelle warns, are likely to worsen inequalities in health care access, which tends to make communities of color more vulnerable. In Kentucky, where Governor Andy Beshear recently celebrated a 30 percent decline in overdose deaths, Shreeta Waldon, executive director of the Kentucky Harm Reduction Coalition, says the reality is more nuanced. While national overdose deaths declined in white populations from 2021 to 2023, for example, they continued to rise among people of color. Black and Latino communities often face barriers when accessing health services, many of which have been shaped by predominantly white institutions. Waldon says it's essential for people from diverse backgrounds to participate in policy decisions and necessary to ensure that opioid abatement funds —legal funds used toward treatment and prevention—are distributed fairly. Without adequate federal funding, Waldon predicts treatment programs in Kentucky will become backlogged—potentially pushing more people into crisis situations that lead to emergency services or incarceration rather than to recovery. These financial and political pressures are not only making it harder to find support for people in crisis; they also reduce opportunities to discuss community needs. Waldon says she knows some social workers who now avoid terms such as 'Black woman' or 'marginalized' in grants and public talks out of fear of losing funding. But people currently needing treatment for substance-use disorder are not necessarily aware of the federal funding news—or 'what's about to hit them when they try to go get treatment and they're hit with barriers,' Waldon says. 'That's way more important to me than trying to tailor the way I talk.' Funding and staffing cuts don't just limit resources for the people most in need. They limit the ability to understand where someone is coming from, which undermines efforts to provide meaningful care, Martínez says. Harm reduction is more than the services and physical tools given to community members, he says. It's about the approach. 'When you look at a whole person, you plant the seed of health and dignity,' he says. 'If everybody deserves a chance at redemption, then we've got to rethink how we're approaching things.'
Medscape
an hour ago
- Medscape
AI Device Enhances Skin Cancer Diagnosis in Primary Care
An artificial intelligence (AI)–enabled handheld elastic scattering spectroscopy (ESS) device improved the sensitivity for skin cancer diagnosis and management by primary care physicians (PCPs), with better overall diagnostic accuracy. METHODOLOGY: ESS is a sampling technique that distinguishes between benign and malignant tissue without surgical biopsy and the ESS device is cleared by the US Food and Drug Administration for use by nondermatologist expert physicians. An AI-enabled handheld ESS device was developed to aid PCPs in the management of suspicious skin lesions. This companion study of the DERM-SUCCESS study conducted across 22 primary care sites in the United States evaluated the impact of the device on PCPs' diagnostic performance in the detection and management of skin cancer. The study involved 108 PCPs (65.7% men) who assessed 50 skin lesion cases (25 benign and 25 malignant) from 50 patients (median age, 59 years; 100% White individuals) in two phases: First, with visual assessment without using the handheld device, followed by an assessment using the device, separated by a 2-hour break. For each lesion, they provided a diagnosis, management decision, and level of confidence in their assessment. The validated device emitted light pulses over specific areas of a lesion to analyze lesion structure and classified lesions as 'Investigate Further' or 'Monitor,' with a 1-10 score reflecting the degree of similarity to malignant lesions. The coprimary endpoints were (1) the referral sensitivity of physicians, a measurement of the ability to appropriately refer malignant cases for further evaluation (management sensitivity) and (2) the referral sensitivity and specificity of physicians who knew the device results. Biopsy results served as the reference standard for both. TAKEAWAY: Management sensitivity was higher for physicians after using the AI-enabled device compared with when they did not have the device results (91.4% vs 82%; P = .0027). PCPs' diagnostic sensitivity also increased from 71.1% without the use of the AI device to 81.7% with the use of the AI device ( P = .0085). = .0027). PCPs' diagnostic sensitivity also increased from 71.1% without the use of the AI device to 81.7% with the use of the AI device ( = .0085). Device-aided management and diagnostic specificity decreased, though not significantly. The use of the device led to 11.8% more benign lesions being incorrectly referred but also led to 9.4% more malignant lesions being correctly referred. In physician management decisions, the proportion of high-confidence assessments increased from 36.8% without the use of the device to 53.4% after the use of the device, and the observed area under the curve performance improved from 0.708 to 0.762. PCPs using the device were better at detecting malignant lesions than by chance (odds ratio, 6.8; P < .0001). Most PCPs reported benefits from the device, including improved confidence in clinical assessments and management decisions. IN PRACTICE: 'The findings demonstrate that utilization of the ESS device output may improve physician performance in the management of suspicious lesions and referral of skin cancer to ensure timely diagnosis,' the authors of the study wrote. SOURCE: This study was led by Laura K. Ferris, of the Department of Dermatology at The University of North Carolina at Chapel Hill. It was published online on May 30, 2025, in Journal of Primary Care & Community Health . LIMITATIONS: The device could not directly affect how PCPs managed lesions owing to the study design because the device was experimental. Clinical information was provided, but the PCPs could not perform hands-on evaluations, which did not reflect real clinical practice but aligned with telemedicine. The study included only White patients, which limited the results for the assessment of different skin types. DISCLOSURES: This study was funded by DermaSensor, Inc. The authors declared no relevant conflicts of interest.
CBS News
an hour ago
- CBS News
Map shows NYC air quality alert expands to Long Island today
First Alert Weather: Expected to be hottest day of year so far First Alert Weather: Expected to be hottest day of year so far First Alert Weather: Expected to be hottest day of year so far New York City faces another air quality alert Thursday, along with more of the surrounding area. The alert will be in effect from 11 a.m. to 11 p.m. for the city, as well as Long Island, the Hudson Valley and Connecticut. Much of the region was also under an air quality alert Wednesday, but Long Island was not included. Now, parts of New Jersey that were included Wednesday have been removed. CBS News New York Expect another day of hazy skies as smoke and haze continue to funnel in from fires burning in Canada's prairie provinces. The smoke and haze, along with rising humidity levels, will contribute to diminished air quality levels today. The good news is that the haze will gradually dissipate over the next few days, leading to improving air quality levels. CBS News New York The hottest day of 2025, so far, is likely to occur today, with highs reaching the upper 80s to low 90s. As the humidity creeps up, a stray shower or storm may develop to the north and west of the city in the afternoon. Air Quality Index (AQI) today CBS News New York An air quality alert is issued when the Air Quality Index exceeds 100. Today, it's expected to be around 108, slightly higher than Wednesday. The AQI measures air pollution and the associated health risks. The system has six ratings: Good (green): 0 to 50 Moderate (yellow): 51 to 100 Unhealthy for sensitive groups (orange): 101 to 150 Unhealthy (red): 151 to 200 Very unhealthy (purple): 201 to 300 Hazardous (marron): 301 and higher Sensitive groups include people with heart or lung disease, older adults, children and pregnant women. What makes the air quality so bad CBS News New York New York City's air quality often suffers in the summer, especially during heat waves, due to higher temperatures and humidity levels. Stagnant air traps pollutants from cars and factories, creating high levels of fine particulates that react to sunlight and lead to respiratory issues. Sometimes, though, air quality alerts have nothing to do with pollution. In June 2023, smoke from that season's Canadian wildfires blew directly into New York City, leading to an extremely hazardous AQI of 484 -- not only the highest ever recorded in the city, but the worst air quality in the entire world on that date. Tracking storms to end the week CBS News New York For tonight, clouds thicken, and it will be warm and muggy, with lows in the mid 60s to low 70s. As for Friday, another warm and humid day is expected, but not as hot as today. Morning sunshine will give way to afternoon showers and thunderstorms. The severe threat is low, though. A chance of storms lingers into Saturday, with even higher levels of humidity. Stick with our First Alert Weather team for the latest forecast, live radar and weather alerts.
